Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, Il Suk | - |
dc.contributor.author | Kim, Chong-Jin | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Youn, Ho-Joong | - |
dc.contributor.author | Jeon, Hui-Kyung | - |
dc.contributor.author | Ihm, Sang Hyun | - |
dc.contributor.author | Cho, Eun Joo | - |
dc.contributor.author | Chung, Woo-Baek | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Kim, Woo-Shik | - |
dc.contributor.author | Nam, Chang-Wook | - |
dc.contributor.author | Park, Seong-Mi | - |
dc.contributor.author | Choi, Ji-Yong | - |
dc.contributor.author | Kim, Young-Kwon | - |
dc.contributor.author | Hong, Taek-Jong | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Cho, Jang-Hyun | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Yoon, Jung-Han | - |
dc.contributor.author | Yang, Tae-Hyun | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Lee, Jun-Hee | - |
dc.contributor.author | Park, Joong-Il | - |
dc.date.accessioned | 2021-09-03T03:27:50Z | - |
dc.date.available | 2021-09-03T03:27:50Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-08 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/82690 | - |
dc.description.abstract | Purpose: Intensive blood pressure (BP) lowering is important for the treatment of hypertension; however, it has been a challenge to achieve target BP in many patients. The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension. Methods: This Phase II multicenter, randomized, double-blind clinical trial enrolled patients aged 19 years or older with essential hypertension, defined as a mean sitting diastolic BP (msDBP) between 95 and 115 mm Hg, and a mean sitting systolic BP (msSBP) of <200 mm Hg after a 2-week placebo run-in period. A total of 635 ilatients were screened, of whom 439 were randomized to receive treatment; 425 patients were included in the full analysis set (combination therapy, 212; monotherapy, 213). Participants were randomly assigned to receive 1 of 8 treatments: CAN (8 or 16 mg), AML (5 or 10 mg), CAN/AML (8 mg/5 mg, 8 mg/10 mg, 16 mg/5 mg, or 16 mg/10 mg), once daily for 8 weeks. Findings: After 8 weeks of treatment, changes in msDBP were significantly greater in the groups receiving CAN/AML combination therapies compared with monotherapies at matched doses, with the exception of CAN 8 mg/AML 10 mg versus AML 10 mg. The response to treatment and the achievement of target BP (both msSBP and msDBP) at week 8 were significantly greater overall in the groups that received combination therapy versus monotherapy. All medications were relatively well tolerated in each group. (C) 2017 Published by Elsevier HS Journals, Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | HIGH BLOOD-PRESSURE | - |
dc.subject | OUTCOMES | - |
dc.subject | PREVENTION | - |
dc.subject | OLMESARTAN | - |
dc.subject | VALSARTAN | - |
dc.subject | REGIMENS | - |
dc.title | Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Seong-Mi | - |
dc.identifier.doi | 10.1016/j.clinthera.2017.06.014 | - |
dc.identifier.scopusid | 2-s2.0-85024864077 | - |
dc.identifier.wosid | 000409399200010 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.39, no.8, pp.1628 - 1638 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 39 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1628 | - |
dc.citation.endPage | 1638 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | HIGH BLOOD-PRESSURE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | OLMESARTAN | - |
dc.subject.keywordPlus | VALSARTAN | - |
dc.subject.keywordPlus | REGIMENS | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | candesartan | - |
dc.subject.keywordAuthor | combination | - |
dc.subject.keywordAuthor | hypertension | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.